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Abstract
Background: HBV and HIV share similar transmission routes. Concurrent infection with the two viruses usually
results in more severe and progressive liver disease, and a higher incidence of cirrhosis, liver cancer and mortality.
Further, this co-infection may lead to cross-resistance between HIV and HBV drugs and increased liver injury, either
due to direct hepatotoxicity or drug-related immune-reconstitution hepatitis. These challenges necessitate
continuous surveillance for HBV among HIV infected individuals to guide patient management. We conducted this
study to understand the serologic and genotypic characteristics of HBV among HIV/HBV infected patients in South
West and Littoral Regions of Cameroon.
Methods: Plasma samples were screened for HBsAg, HBeAg, Anti-HBs and anti-HBc using ELISA followed by DNA
extraction from all HBsAg positive samples. A 366 bp region covering the overlapping surface/polymerase gene was
amplified by a nested PCR and the product sequenced using Big Dye sequencing chemistry. The resulting
sequences were then analyzed for genotypes and both escape and drug resistance mutations.
Results: Of the 455 samples in this study, 25.5 % (n = 116) were HBsAg positive and 46 of these had their DNA
successfully amplified. Genotype E was found in 32 samples (69.6 %) and genotype A in the rest of the samples.
Escape mutations associated with failure of diagnosis (Y100C, R122K and Q129H) and with vaccine escape (Q129R
and T131N) were detected in varying frequencies in the population. Polymerase mutations implicated in resistance
to lamivudine and other ʟ-nucleoside analogues were detected in seven patients (15.2 %), while all the samples
lacked mutations associated with resistance to adefovir and tenofovir.
Conclusions: These findings suggest the endemicity of HBV and the predominance of genotypes A and E in the
study population. Also, drug resistance findings support the use of tenofovir based ART regimens among HIV/HBV
co-infected persons. There is need for continuous HBV screening and monitoring in HIV infected individuals in
these regions.
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Background
Hepatitis B virus (HBV) [Family Hepadnaviridae, Genus
Orthohepadnavirus] is estimated to infect more than
300 million people worldwide and is a common cause of
liver disease and liver cancer [1]. The virus contains a
partly double-stranded DNA genome with approximately
3200 base pairs. It replicates via an RNA intermediate anti-
genome sequence, encoding a potentially error-prone poly-
merase enzyme with both reverse transcriptase and DNA
polymerase activities [2]. HBV infection is associated with
a wide spectrum of clinical manifestations. The outcome of
acute infection may range from asymptomatic hepatitis to
fulminant liver failure. Failure of viral clearance following
acute infection may result in inactive carriage or chronic
hepatitis which can progress to both cirrhosis and hepato-
cellular carcinoma (HCC) [1]. The toll of approximately
1 million deaths from chronic liver disease and hepato-
cellular carcinoma per year is a clear demonstration of
the global health problem posed by this virus [3].
The diagnosis of HBV infection and its associated
disease is based on a constellation of clinical, biochemical,
histological, and serologic findings [1]. Routinely, it is di-
agnosed by the presence of the hepatitis B surface antigen
(HBsAg) and antibodies to the hepatitis B core antigen
(anti-HBc). HBsAg may be detected as early as 1–2 weeks
or as late as 11–12 weeks after exposure. Individuals with
HBsAg in their serum have overt HBV infection, but do
not necessarily have active liver disease; its persistence is
considered a marker of chronicity. Hepatitis B e antigen
(HBeAg) is a surrogate marker of HBV replication and
correlates with the presence of high HBV DNA levels and
infectivity. Anti-HBc usually appears in the acute phase of
HBV infection and persists for a long time after virus
clearance while the presence of anti-HBs with anti-HBc
usually indicates a past, resolved infection. In the absence
of HBsAg, serum anti-HBs indicate protective immunity
against HBV acquired by vaccination (anti-HBc-negative)
or natural infection (anti-HBc-positive) [4].
Due to the lack of proof-reading activity of DNA
and RNA dependent DNA polymerase, nucleotide
mis-incorporation occurs during HBV replication.
This is responsible for the emergence of different
HBV genotypes and subtypes [5]. These genotypes
are defined by inter-genotypic differences of more
than 7.5 % in the complete HBV genome. Currently,
HBV isolates are classified into 10 genotypes (A–J)
and several subtypes, with a differential geographic
distribution [6]. Besides differences in geographical
distribution, the clinical significance of the genotypes
has also been demonstrated. Several studies have
shown that genotypes play an important role in
treatment management and also in disease prognosis
[7, 8]. Information on genotypes is therefore import-
ant in identifying patients who are at an increased
risk of adverse outcomes and in choosing optimal
therapy.
Both HBV and the human immunodeficiency virus (HIV)
share common routes of blood-borne and sexual transmis-
sion, but they differ in efficiency of transmission and in
their geographic distribution [9]. In patients co-infected
with HBV and HIV, it has been demonstrated that the HBV
X-protein (HBx) super-induces ongoing HIV-1 replication
and HIV-1 long-term repeated transcription by synergizing
with tat- protein and with T-cell activation signals [10].
These findings indicate that HBx could contribute to a fas-
ter progression to AIDS in HBV/HIV-co-infected individ-
uals [11]. In both viruses, lamivudine (3TC), a nucleoside
analogue is widely used as part of the treatment [12]. The
major limitation in the use of lamivudine is the selection of
resistant mutants, which affect the tyrosine– methionine–
aspartate (YMDD) motif of the HBV DNA polymerase. It
has been shown that when lamivudine-resistant variants
emerge, HBV DNA levels increase, liver enzyme levels may
rise, and the resulting hepatitis can be fatal in a minority of
patients. In addition, the bulk of available data suggest that
the benefit in preventing progression of liver disease is sub-
stantially diminished with the presence of lamivudine-
resistant HBV [13]. Furthermore, the use of lamivudine in
an HIV/AIDS treatment regimen, as the only anti-HBV
component is an unintended monotherapy against HBV in
HIV/HBV infected patients, with the potential to select for
HBV lamivudine resistance.
Several studies have demonstrated high rates of Hepa-
titis B and C and HIV infections among HIV infected
patients in Cameroon [14, 15]. However, studies in this
region focusing on genotypic characterization, analysis
of HBV vaccine escape mutants and lamivudine resist-
ance have only started to emerge [16]. We thus sought
to investigate the prevalence and genotypic profile of
hepatitis-B infection among HIV-infected individuals in
South West and Littoral regions of Cameroon.
Methods
Study setting
The study participants were outpatient clients of the
Mutengene Baptist Health Centre located in the South
West Region of Cameroon. The Health Centre offers HIV /
AIDS treatment, prevention, medical, spiritual and psycho-
social care in the Tiko Health District. The hospital attends
to at least 8000 patients per month. Patients come from
various towns such as Buea, Limbe, Tiko, Kumba in the
South West Region, and Douala, Nkongsamba, in the
Littoral Region often because of the good quality of care
accorded in this facility. These towns are shown in Fig. 1.
Study population and ethical considerations
This was a retrospective laboratory-based study and a
total of 455 archived HIV positive plasma samples were
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used. The study protocol was approved by the institu-
tional review board of the Cameroon Baptist Health
Board, Cameroon (IRB2012-01) and the Research Ethics
Committee of the University of Venda, South Africa
(SMNS/14/MBY/21/2110). Written informed consent
was obtained from all study participants or their legal
guardians prior to their recruitment.
Sample collection and processing
Five millilitres of venous blood was collected once from
each consenting HIV positive adult individual using
EDTA vacutainer tubes between February and December
2013. Two ml of blood was collected from young chil-
dren. Blood was centrifuged for 5 min at 3578Xg. Fol-
lowing centrifugation, plasma was aspirated aseptically
and aliquoted into sterile labelled cryotubes and stored
at -80°c. These were then transported on dry ice to the
HIV/AIDS & Global Health Research laboratories at the
University of Venda, South Africa where they were
stored at -80°c until used.
HBV serologic markers
All plasma samples were screened using a commercially
available enzyme-linked immunosorbent assay (ELISA) for
the presence of HBsAg (Bioelisa, Biokit, Barcelona, Spain).
This kit utilizes a sandwich ELISA format using guinea pig
anti-HBs antibodies coated to microplate wells which act as
the capture antibody and goat anti-HBs antibodies marked
with peroxidase which serve as conjugate antibodies.
HBsAg positive samples were then screened for HBeAg by
ELISA (DRG Instruments GmbH, Germany) while HBsAg
negative samples were also screened for anti-HBc and anti-
HBs (DRG Instruments GmbH, Germany).
DNA extraction
DNA from all HBsAg positive samples was extracted
from 100 μl of plasma using the Quick-gDNA mini prep
(Zymo research, USA) according to the manufacturer’s
instructions. The extracted DNA was amplified immedi-
ately after extraction or stored at −20 °C for subsequent
amplification.
Polymerase chain reaction for HBV surface/polymerase
gene
A nested PCR was performed in order to amplify the
overlapping surface/polymerase gene covering nucleo-
tides 403–768 from the EcoR1 site as described previ-
ously [17]. The first round reaction was conducted in a
50 μl volume containing 10 mM Tris-HCI pH 8.3,
50 mM potassium chloride, 0.2 mM dNTP mix, 2.5 mM
Fig. 1 Panel a: The map of Cameroon showing the South West region (highlighted), from where most of the study participants originated from.
Panel b: The towns (circled blue) from where the study participants originated from. The Mutengene Baptist Health Centre (indicated in red, with
an asterix) is located in the South West region. (Adapted from Google maps, accessed on 21 June 2015 21:18 pm)
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magnesium chloride, 0.2 ng/μl of each primer, and 2
units of Taq polymerase (Applied Biosystems, PE, Italia).
The samples were subjected to 35 cycles involving de-
naturation at 95 °C for 1 min, annealing at 55 °C for
1 min, and extension at 72 °C for 1 min. Five μl of the
first round PCR product was used as a template for the
nested PCR under the same reaction conditions, but per-
forming only 20 cycles. The PCR products were then re-
solved by 1.5 % agarose gel electrophoresis stained with
ethidium bromide. PCR Amplicons were then purified
using QiAquick PCR Purification Kit (Qiagen, Hilden;
Germany) according to the manufacturer’s instructions.
Sequencing
Purified PCR products were directly sequenced at Inqaba
Biotech (Pretoria, South Africa) according to the Sanger
protocol. Contiguous nucleotide sequences (contigs) were
assembled from resulting forward and reverse reactions
using the SeqMan Pro® module of the Lasergene (version
8.1.5) sequence analysis software suite (DNASTAR.
Madison, WI.).
Sequence analysis
The resulting nucleotide sequences were aligned using the
Clustal W program implemented in MEGA 6.06 [18].
They were also translated and checked for HBsAg muta-
tions in the S gene and drug resistance associated muta-
tions in the P gene. A Maximum Likelihood (ML)
phylogenetic tree with a bootstrap of 3000 replicates was
constructed utilizing the General Time Reversible (GTR)
model using MEGA 6.06 [18]. Frequency estimates of evo-
lutionary divergence between nucleotide sequences were
then estimated using the Kimura 2-parameter model [19]
implemented in MEGA 6.06 [18]. Since the 366 bp frag-
ment sequenced in this study was too short to give reso-
lution for the sub genotypes in the phylogenetic tree (but
sufficient to determine the genotypes), the geno2Pheno
database [20] was used for their prediction. The sequences
from this study have been deposited in GenBank under
accession numbers KU900150-KU900195.
Statistical analysis
The study also determined the impact of the identified
HBV genotypes on HIV progression. Mean CD4 cell
counts among patients infected by the different
genotypes were compared using an independent samples




There were a total of 455 HIV positive participants, of
whom 343 (75.4 %) were females. The mean age of the
patients was 33.8 years (range, 1 to 68 years) while the
mean CD4 counts were 406 cells/μl. In terms of their
HIV clinical staging, 127 were in clinical stage 1, 166 in
stage 2, 198 in stage 3 and 89 in stage 4. A total of 157
participants were not yet on ART at the time of sample
collection. Majority of those on ART were on
Zidovudine, Lamivudine and Nevirapine.
Serology
The HBsAg was positive in 116/455 patients resulting in
a 25.5 % prevalence. Of the 116 HBsAg positive patients,
90 (26.2 %) were females and 26 (23.2 %) were males
while only 9 (7.8 %) were children below 14 years. Sam-
ples positive for HBsAg (n = 116) were also tested for
HBeAg, and 15.7 % (16/102) were positive (14 samples
were not screened due to insufficient volumes). Among
the HBeAg positive samples, 25 % (4/16) were from
children aged below 14 years. Samples that were nega-
tive for HBsAg (n = 339) were tested for anti-HBs and
anti-HBc, of which 13.3 % (44/331) were positive for
anti-HBs, and 36.3 % (120/331) were positive for anti-
HBc (8 samples were not screened due to insufficient
quantity). 20.8 % (69/331) of the patients were positive
for both anti-HBc and anti-HBs.
Prevalent HBV Genotypes
HBV DNA was successfully amplified in 41 % (n = 48)
of the HBsAg positive samples. Sequencing of the
overlapping surface/polymerase gene was successful
for 46 out of these 48 HBV-DNA positive samples.
Phylogenetic analysis revealed two prevalent genotypes
namely A and E. HBV genotype E was identified in
69.6 % (n = 32) and HBV genotype A in 30.4 % (n = 14)
of the participants. Figure 2 shows the phylogenetic
relationships of the studied viruses. Of the 14 genotype
A viruses, 13 were categorized as sub genotype A1 and
1 as sub genotype A2 by Geno2Pheno analysis. HBV
genotype E infected patients had a slightly higher
mean CD4 cell count (390 cell/μl) compared to geno-
type A infected patients (304 cell/μl). However, this
difference was not statistically significant (p = 0.486).
HBV genetic diversity
Analyses of nucleotide sequence identity among HBV
genotype A from this study indicate that they were 94–
100 % similar with an average identity of 96.9 %. Among
genotype E, the sequence identity was 97.8 – 100 % with
an average identity of 99.4 %.
HBsAg escape mutants
Mutations within the major hydrophilic region (MHR)
of the S gene and which are associated with poor
reactivity in serological assays and also immune escape
were described. A total of 16 mutations occurring in at
least three samples within this region were noted. The
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most prevalent mutations observed were found either in
the ‘a’ region (L127P, S140T and S143T) or the B cell
epitope and its surrounding region (G159A, F161Y and
A168V). Generally, more mutations were observed
within genotype A than genotype E. This is shown in
Table 1.
Drug resistant mutations
HBV polymerase mutations associated with resistance
to lamivudine and other drugs used in treatment were
determined. These mutations were detected in seven
patients; six among genotype A and one among geno-
type E. Mutations rtV173L, rtL180M, rtM204V confer-
ring resistance to lamivudine and other ʟ-nucleoside
analogues were identified in six patients while one
patient had the rtL180M + rtM204V + rtT184S muta-
tions associated with resistance to both ʟ-nucleoside
analogues and entecavir. Three of the patients with
lamivudine resistant HBV had no prior exposure to
the drug as part of HIV treatment. Mutations confer-
ring resistance to tenofovir and adefovir were not
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Fig. 2 A maximum likelihood rooted phylogenetic tree of HBV sequences from HBV/HIV co-infected individuals from Cameroon. The tree also
contains selected global sequences covering the gene region 403–768 from the EcoR1 site. The 46 viruses characterised in this study are
indicated with a black circle and fall into genotypes E and A. All reference sequences are labeled with their genotype/sub genotype, accession
number and country of origin. Bootstrap values >70 % are shown. The tree is rooted with the Wooley monkey virus sequence
Table 1 Mutations found within the major hydrophilic region
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Discussion
In the present study, the prevalence of HBsAg among
the study participants was found to be 25.5 %. This sero-
prevalence is higher than that from recent studies in
Cameroon [14, 16, 21]. In these studies, study partici-
pants were largely drawn from one town either Yaoundé
or Buea. However, it is comparable to the 20.4 % ob-
tained in a study involving pregnant mothers in northern
Cameroon [22]. This confirms the hyper endemic nature
of HBV in this country. It should also be noted that the
high HBsAg sero-prevalence in this study is in coher-
ence with published data within central sub-Saharan
Africa. In this region the reported HIV/HBV fre-
quency varies from 0 to >28.4 % [23]. Furthermore, it
is important to note that HBV sero-prevalence differs
intranationally in some countries with areas of high
endemicity.
Children aged 14 years and below had the lowest
HBsAg prevalence (7.8 %) in comparison to the other
age groups. On the other hand, an HBeAg positivity of
44.4 % (4/9) among children aged below 14 years result-
ing in a prevalence of 3.9 % (4/102) was documented.
Considering that horizontal infection during early child-
hood is the main route of transmission in high
prevalence communities [24], the low HBsAg prevalence
in children might be due to the integration in 2005 of
the HBV vaccine into the expanded program on
immunization (EPI) in Cameroon. It is thus expected
that most of the children in the 1–14 years old age
group might have been vaccinated. Of concern however
is the HBeAg prevalence in this group. Since these chil-
dren are likely to have been vaccinated and yet had evi-
dence of viral replication, we postulate that either they
were more than 9 months old by the time the vaccin-
ation was rolled out and were thus not vaccinated or
that they were infected with immune escape mutants.
Since this early infection may lead to chronic hepatitis
and increased risk of liver cancer, this observation
warrants further studies.
HBsAg is a marker of active HBV infection. However,
HBV DNA was successfully amplified only in 41 % of
the HBsAg-positive patients. This is not surprising as in-
active HBsAg carriers (diagnosed by absence of HBeAg
and undetectable or low levels of HBV DNA) have been
shown to form the largest group in chronic HBV in-
fected patients [25]. It has also been shown that HBsAg
levels are not always associated with serum HBV DNA
levels since HBsAg synthesis can occur independent of
HBV replication [26]. Several studies from the same re-
gion have reported HBV DNA amplifications of 47 %
from HBsAg positive samples [22, 27]. The phylogenetic
analysis of the overlapping surface/polymerase gene cov-
ering nucleotides 403–768 from the EcoR1 of HBV in
this study reveals the predominance of genotype E in the
study population. This observation is in agreement with
previous studies that have shown the endemicity of this
genotype to the ‘genotype E crescent’, which spans from
Senegal to Namibia in the South and to the Central
African Republic in the East [28, 29]. HBV genotype A
was also identified in this study albeit at a lower fre-
quency than genotype E. This trend has also been shown
recently [16]. In contrast, several studies have shown the
dominance of genotype A in Cameroon [28, 30]. Since
both genotype A and E circulate in this country, their
relative distribution has been shown to vary depending
on the cohort being studied [22].
Concerning the genetic diversity among the identified
genotypes, this study observed that genotype E was more
conserved with a diversity of 0.6 % compared to 3.1 % in
genotype A. Genotype A is significantly heterogeneous
and more diverse in Africa suggesting an African origin.
This diversity has occasioned its further classification
into several sub genotypes and variants [5]. The low
intra-genetic diversity of genotype E compared to other
genotypes has been described previously [31]. This find-
ing coupled with its presence in West Africa and ab-
sence in the Americas in most studies has led to the
suggestion that the introduction of genotype E into the
human population is a recent event [5]. However, some
studies have suggested that its evolutionary history is
not as recent as previously thought.
Mutations in the HBsAg are known to allow escape
from neutralizing antibodies and also lead to no or poor
reactivity with serological assays. Most of these muta-
tions occur in the major hydrophilic region spanning
amino acid 99–169 within which there is the ‘a’ deter-
minant (amino acid 120 to 147), the most antigenic part
of the S gene [32]. We thus sought to investigate the
mutations in this region. In agreement with the genetic
diversity results, more mutations were observed among
genotype A than E sequences. There were three escape
mutations identified which were previously associated
with diagnostic failure (Y100C, R122K and Q129H) and
two associated with vaccine escape (Q129H and T131N).
The reason some mutations previously linked with








272CMR A rtV173L, rtL180M, rtM204V Yes (51)
276CMR A rtV173L, rtL180M, rtM204V Yes (4)
247CMR A rtV173L, rtL180M, rtM204V Naive
438CMR E rtL180M, rtT184S, rtM204V Naive
369CMR A rtV173L, rtL180M, rtM204V Yes (24)
467CMR A rtV173L, rtL180M, rtM204V Yes (48)
586CMR A rtV173L, rtL180M, rtM204V Naive
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diagnostic failure were detected in this study might be
because the ELISA kit (Bioelisa, Biokit, Barcelona, Spain)
used in this study has been shown to detect some of
these mutants [33]. We however hope to investigate in
the near future mutations in the HBsAg negative sam-
ples. The prevalence of vaccine escape mutations was
found to be low in this population. Considering that
HBV vaccination was incorporated into the Cameroon
national EPI in 2005, this is in agreement with the obser-
vation that such mutations develop slowly [34].
Different HBV variants or mutants, i.e., viral quasi spe-
cies, are selected within the same host in response to anti-
viral therapy during the course of infection. This coupled
with the fact that primary resistance to any individual drug
appears to confer at least some degree of cross-resistance
to other drugs presents a significant clinical challenge
since remaining treatment options are limited [35]. This
study observed previously described drug mutations in
seven patients, three of whom had no experience with
ARVs. The replacement of methionine in the YMDD cata-
lytic site motif by valine (rtM204V) in the seven patients
is associated with resistance to lamivudine and other ʟ-nu-
cleoside analogues. The mutation rtL180M found together
with the rtM204V mutation in these patients is associated
with resistance to telbivudine and also with enhanced
replication [35]. The rtV173L mutation found in six of
these patients is known to compensate for replication de-
fects of lamivudine resistant HBV mutants [36]. The
rtL180M+ rtT184S + rtM204V triple mutation found in
one patient suggests resistance to entecavir, lamivudine
and other ʟ-nucleoside analogues. Importantly, no resist-
ance mutations associated with the acyclic nucleoside
phosphonates namely adefovir and tenofovir were identi-
fied. This supports the recommendation by the WHO that
tenofovir be made available in the Cameroonian AIDS
program for use in HIV/HBV co-infected patients [27].
Three of the seven patients with drug resistant HBV
were ARV naïve. This observation in which resistance
occurs in ARV naïve patients has also been made previ-
ously [37, 38]. It is not clear whether the HBV in these
patients actually developed de novo lamivudine-resistant
mutations or that the patients were infected with
lamivudine-resistant viruses that persisted. Some pos-
sible explanations for the presence of lamivudine-
resistant HBV in the untreated Cameroonian HIV/HBV
co-infected patients could be suggested. In a country
where lamivudine is the backbone of HIV treatment, we
may be constrained to speculate that this may arise from
infection with a lamivudine resistant HBV strain ac-
quired from an HIV infected individual currently on
treatment but also co-infected with HBV. Overall, these
results emphasize the need for sporadic HBV drug re-
sistance screening among HIV/HBV co-infected patients
before therapy initiation.
The lack of HBV and HIV viral load data together with
liver enzyme levels in this study preclude our ability to
correlate the results reported here with clinical out-
comes. Furthermore, since this study focused only on
HBsAg positive samples, it is possible that more geno-
types would have been identified. This is because occult
infection (HBV DNA in the absence of HBsAg) is known
to occur. Nevertheless, this study provides added in-
sights into the circulating HBV genotypes and variants
in this region.
Conclusions
In conclusion, our results confirm the endemicity of
HBV in South West and Littoral regions of Cameroon
and the circulation of genotypes E and A. In line with
the WHO recommendations, this study supports tenofo-
vir based regimens in the treatment of HBV in HIV/
HBV co-infected persons. There is need for continuous
monitoring of HBV drug resistance in this population
and more studies comparing HBV in HIV infected and
uninfected individuals are recommended.
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